Three Studies Support Medtronic’s Cryoablation Systems As ‘First Line’ AFib Treatment
Executive Summary
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
You may also be interested in...
FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib
The new approval allows Medtronic to promote cryoablation as the first option for patients with recurrent symptomatic paroxysmal atrial fibrillation. Previously, it was only approved for patients who had already tried to manage their atrial fibrillation with drugs.
Medtronic, Farapulse Advance Pulsed Field Ablation With US Trials
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
Medtronic Claims Share Gains In Cardiovascular And Neurostim
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.